FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A

[1]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[2]  Jia-geng Zhu,et al.  FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy. , 2019, Cancer letters.

[3]  Y. Niu,et al.  Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer , 2019, Disease markers.

[4]  Ju-Seog Lee,et al.  FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. , 2019, Carcinogenesis.

[5]  Q. Cao,et al.  The Identification of Potential Biomarkers and Biological Pathways in Prostate Cancer , 2019, Journal of Cancer.

[6]  E. Lam,et al.  FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression , 2019, Scientific Reports.

[7]  P. Laissue.  The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis , 2019, Molecular Cancer.

[8]  Y. Park,et al.  High FOXM1 expression is a prognostic marker for poor clinical outcomes in prostate cancer , 2019, Journal of Cancer.

[9]  P. Kantoff,et al.  Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. , 2019, European urology.

[10]  Ming-Fen Lee,et al.  MED28 and forkhead box M1 (FOXM1) mediate matrix metalloproteinase 2 (MMP2)‐dependent cellular migration in human nonsmall cell lung cancer (NSCLC) cells , 2018, Journal of cellular physiology.

[11]  Y. Ohmori,et al.  Silencing of the interferon-inducible gene Ifi204/p204 induces resistance to interferon-γ-mediated cell growth arrest of tumor cells. , 2019, Cytokine.

[12]  M. Gizzi,et al.  Advancing therapies in metastatic castration-resistant prostate cancer , 2018, Expert opinion on pharmacotherapy.

[13]  Zhaojian Liu,et al.  PCNA‐associated factor P15PAF, targeted by FOXM1, predicts poor prognosis in high‐grade serous ovarian cancer patients , 2018, International journal of cancer.

[14]  Yue Li,et al.  Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer , 2018, Cancer management and research.

[15]  Ze Zhang,et al.  FOXM1 regulates radiosensitivity of lung cancer cell partly by upregulating KIF20A , 2018, European journal of pharmacology.

[16]  Y. Rojanasakul,et al.  Synergistic effect of black tea polyphenol, theaflavin-3,3'-digallate with cisplatin against cisplatin resistant human ovarian cancer cells. , 2018, Journal of functional foods.

[17]  Xuegong Fan,et al.  FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness , 2018, Cell Death & Disease.

[18]  Yangyang Fu,et al.  Aberrant KIF20A expression might independently predict poor overall survival and recurrence‐free survival of hepatocellular carcinoma , 2018, IUBMB life.

[19]  J. Chung,et al.  Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1 , 2018, BMB reports.

[20]  Guoqiang Yan,et al.  Paeoniflorin inhibits cell growth and induces cell cycle arrest through inhibition of FoxM1 in colorectal cancer cells , 2018, Cell cycle.

[21]  Yifei Liu,et al.  FoxM1 overexpression promotes cell proliferation and migration and inhibits apoptosis in hypopharyngeal squamous cell carcinoma resulting in poor clinical prognosis , 2017, International journal of oncology.

[22]  W. De,et al.  Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer , 2017, Oncotarget.

[23]  Lunquan Sun,et al.  The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells , 2017, Cell Death & Disease.

[24]  F. Du,et al.  FoxM1-mediated RFC5 expression promotes temozolomide resistance , 2017, Cell Biology and Toxicology.

[25]  Lijun Xue,et al.  FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10 , 2016, Oncotarget.

[26]  D. Sinclair,et al.  O-GlcNAcylation regulates breast cancer metastasis via SIRT1 modulation of FOXM1 pathway , 2016, Oncogene.

[27]  Lijun Xue,et al.  FOXM 1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC 10 , 2017 .

[28]  Wei Huang,et al.  Positive expression of KIF20A indicates poor prognosis of glioma patients , 2016, OncoTargets and therapy.

[29]  Xue Zhu,et al.  FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant A549 cells to docetaxel via activation of JNK/mitochondrial pathway. , 2016, Acta biochimica et biophysica Sinica.

[30]  C. Creighton,et al.  Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer , 2016, Nature Communications.

[31]  Hua Lu,et al.  Aberrantly activated Gli2-KIF20A axis is crucial for growth of hepatocellular carcinoma and predicts poor prognosis , 2016, Oncotarget.

[32]  Lara J. Monteiro,et al.  Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance , 2015, Oncogene.

[33]  K. L. Silva,et al.  FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance. , 2015, Cellular signalling.

[34]  C-YF Huang,et al.  Identification of thiostrepton as a novel therapeutic agent that targets human colon cancer stem cells , 2015, Cell Death and Disease.

[35]  She Chen,et al.  Overexpression of BIRC6 Is a Predictor of Prognosis for Colorectal Cancer , 2015, PloS one.

[36]  J. Chien,et al.  Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells , 2014, Oncotarget.

[37]  B. Katzenellenbogen,et al.  The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells , 2014, Breast Cancer Research.

[38]  Jun Liang,et al.  FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin , 2014, Journal of cellular and molecular medicine.

[39]  K. Xie,et al.  FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System , 2014, Clinical Cancer Research.

[40]  Y. Doki,et al.  Overexpression of Forkhead Box M1 Transcription Factor (FOXM1) is a Potential Prognostic Marker and Enhances Chemoresistance for Docetaxel in Gastric Cancer , 2013, Annals of Surgical Oncology.

[41]  P. Wei,et al.  The Critical Role of Dysregulated FOXM1–PLAUR Signaling in Human Colon Cancer Progression and Metastasis , 2012, Clinical Cancer Research.

[42]  Ju-Seog Lee,et al.  Abstract 2962: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair , 2012 .

[43]  Satoki Nakamura,et al.  The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. , 2010, Carcinogenesis.

[44]  Dong Liu,et al.  Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro , 2010, Acta Pharmacologica Sinica.

[45]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..